TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million TG Therapeutics (NASDAQ: TGTX) secured a new five-year $750 million senior secured credit facility with funds managed by Blue Owl, repaid its prior $250 million facility and thus raised 500 million of net non-dilutive capital. The facility can be increased by $250 million to a total of $1 billion at mutual discretion.The Board expanded the share repurchase program from $100 million to $300 million; as of March 18, 2026 the company repurchased about $38 million of stock at an average price of $28.98. Further credit-facility details will be filed on Form 8-K.

#TGTX TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

www.stocktitan.net/news/TGTX/tg-therapeutic...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.

#DTIL #TGTX Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/DTIL/precision-bio-...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting TG Therapeutics (NASDAQ: TGTX) announced the schedule of data presentations for BRIUMVI (ublituximab-xiiy) at the American Academy of Neurology (AAN) 2026 annual meeting, April 18–22 in Chicago. Two poster presentations on April 21 cover real-world ENABLE Phase 4 experience and ENHANCE safety/tolerability updates. Abstracts are available on the AAN website and data will be posted to the company publications page.

#TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.

#DTIL #TGTX Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

www.stocktitan.net/news/DTIL/precision-bio-...

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance TG Therapeutics (NASDAQ: TGTX) reported fourth-quarter 2025 total revenue of $192.6M and full-year 2025 revenue of $616.3M, driven by BRIUMVI U.S. net revenue of $182.7M (Q4) and $594.1M (FY). The company raised 2026 total global revenue guidance to $875–$900M and expects BRIUMVI U.S. revenue of $825–$850M.Other highlights: completed a $100M repurchase and authorized an additional $100M, presented multi‑year BRIUMVI data, advanced pivotal trials including a subcutaneous program, and ended 2025 with $199.5M cash and investments.

#TGTX TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

www.stocktitan.net/news/TGTX/tg-therapeutic...

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones TG Therapeutics (NASDAQ: TGTX) reported preliminary unaudited results and 2026 guidance on Jan 13, 2026. Full year 2025 total global revenue is approximately $616 million, with BRIUMVI U.S. net product revenue of about $182 million in Q4 and $594 million for full year 2025. For 2026 the company targets $875–900 million in total global revenue, including $825–850 million of BRIUMVI U.S. net product revenue.2026 operating expense target is ~$350 million $100 million for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up. Key development milestones include pivotal topline ENHANCE mid‑2026, Phase 1 azer‑cel data H2 2026, and pivotal subcutaneous BRIUMVI data year‑end 2026/1Q 2027.

#TGTX TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

www.stocktitan.net/news/TGTX/tg-therapeutic...

TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies TG Therapeutics (NASDAQ: TGTX) said it ranked #27 on the 2025 Deloitte Technology Fast 500, a list of North America’s 500 fastest-growing tech and life sciences companies.The company attributed its growth from fiscal years 2021–2024 to BRIUMVI revenues after BRIUMVI received FDA approval in December 2022 to treat adults with relapsing forms of multiple sclerosis. Management credited employee execution, continued product adoption, and patient/provider trust for the result.

#TGTX TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

www.stocktitan.net/news/TGTX/tg-therapeutic...

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million | The Motley Fool Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million

#CHKP #UNFI #CPB #CHTR #B #TGTX #0ffb1979-1623-4b37-bbe6-45af9be0c0e7 #coveragefilings

Origin | Interest | Match

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target to approximately $585 million Conference call to be held today, Monday, November

#TGTX TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

www.stocktitan.net/news/TGTX/tg-therapeutic...

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI TG Therapeutics (NASDAQ: TGTX) announced completion of enrollment in the randomized cohort of the Phase 3 ENHANCE trial testing a consolidated Day 1/Day 15 IV dosing schedule for BRIUMVI (ublituximab) in relapsing multiple sclerosis (RMS) on Oct 28, 2025.The trial's primary endpoint is noninferior exposure measured by AUC at Week 16. ENHANCE is randomized, double-blind and placebo-controlled and will assess pharmacokinetics, safety (including infusion-related reactions), and efficacy via T1 Gd-enhancing lesions. Dosing arms compare a single 600 mg Day 1 dose plus Day 15 placebo versus 150 mg Day 1 then 450 mg Day 15, with a 450 mg dose at Week 24.Company commentary notes potential for a simplified regimen to improve patient convenience and infusion center efficiency and states that, if data are positive, the regimen could be ready for launch in 2027.

#TGTX TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

www.stocktitan.net/news/TGTX/tg-therapeutic...

$100M Buyback Complete: TG Therapeutics Doubles Down with Fresh $100M Share Repurchase Authorization Biotech firm repurchased 3.5M shares at $28.55 average under completed program. New $100M authorization reflects confidence in BRIUMVI drug's multibillion-dollar market potential.

#TGTX TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

www.stocktitan.net/news/TGTX/tg-therapeutic...

TG Therapeutics Q2 Revenue Up 91% | The Motley Fool

#TGTX #735312da-f7f8-4f7b-a238-f68923a8592f #data-news

Origin | Interest | Match

TG Therapeutics Smashes Earnings: BRIUMVI Sales Surge 91%, Company Lifts 2025 Revenue Target Q2 revenue hits $141.1M as MS drug BRIUMVI leads growth. Company raises full-year guidance to $575M and achieves profitability. See detailed results.

#TGTX TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

www.stocktitan.net/news/TGTX/tg-therapeutic...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#JPM, #CSIQ, #ONON, #TGTX, #CSCO

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CNC 28.2x
2. #JPM 12.5x
3. #CSIQ 11.4x
4. #ONON 7.1x
5. #TGTX 6.6x

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PDYN, #TGTX, #DJT, #BULL, #QXO

#OptionFlow #OptionsTrading #Trading

New Clinical Data Reveals BRIUMVI's Impressive Safety Profile in Multiple Sclerosis Treatment Latest real-world and clinical studies demonstrate BRIUMVI's safety in MS patients, including 30-minute infusion tolerability data. See complete findings.

#TGTX TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies: 1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree 2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox 3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.

#TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PTON, #CRWV, #WOLF, #TGTX, #ALLT

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 69% OTM
2. #PTON 41% OTM
3. #CRWV 34% OTM
4. #WOLF 32% OTM
5. #TGTX 32% OTM

#OptionFlow #OptionsTrading #Trading

www.fool.com/investing/2025/05/05/why...

#TGTX #d27a1699-7d05-4c2d-8df2-5d701e07c6b1 #investing

Result Details

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance TG Therapeutics (NASDAQ: TGTX) reported strong Q1 2025 financial results, with BRIUMVI U.S. net revenue reaching $119.7 million, a 137% increase year-over-year. The company raised its 2025 guidance, targeting global net revenue of $575 million and U.S. BRIUMVI revenue of $560 million. Clinical data showed impressive results, with 92% of patients free from disability progression after five years of BRIUMVI treatment. The company reported a net income of $5.1 million in Q1 2025, compared to a $10.7 million loss in Q1 2024. Cash position stands at $276.2 million, with management confident in funding operations based on current projections. TG Therapeutics is advancing several initiatives, including subcutaneous BRIUMVI development and expansion into additional markets through partnership with Neuraxpharm.

#TGTX TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

www.stocktitan.net/news/TGTX/tg-therapeutic...

Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential New clinical data reveals BRIUMVI's single-dose effectiveness in MS treatment, plus promising 5-year results from ULTIMATE studies. See complete analysis inside.

#TGTX TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile New real-world data shows improved tolerability for BRIUMVI in MS patients, with 5-year safety confirmation and launch of major observational study. Full analysis inside.

#TGTX TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short New studies validate BRIUMVI's effectiveness in MS patients switching from other CD20 therapies. Key findings published in leading medical journals. Full analysis inside.

#TGTX TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

www.stocktitan.net/news/TGTX/tg-therapeutic...

Can This MS Drug Change Treatment Standards? Major 5-Year Study Results Coming Five comprehensive studies reveal long-term efficacy and safety data for BRIUMVI in MS treatment, including real-world patient experiences and 5-year clinical outcomes.

#TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

www.stocktitan.net/news/TGTX/tg-therapeutic...

NEWS: ( NASDAQ: #TGTX ) Expected US Company Earnings on Monday, March 3rd, 2025